Investors with a lot of money to spend have taken a bullish stance on Exact Sciences EXAS. And retail traders should know. We noticed this today when the positions showed up on publicly available ...

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the succ ...

Exact Sciences stock bounded higher Thursday after ... following Exact's second-quarter update," Canaccord Genuity analyst Kyle Mikson said in a report. "The company posted solid year-over-year ...

Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday announced that a blood-based test it’s developing showed promise in accurately detecting the disease.

Exact Sciences EXAS continues to make significant progress with its Cologuard test and efforts to expand Oncotype DX overseas. Advancements in the key pipeline programs are highly promising.

Analyst Kyle Mikson CFA of Canaccord Genuity maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price ...

Thank you for standing by. At this time, I would like to welcome everyone to today's Exact Sciences second quarter 2024 ...

Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly challenge his rival to a bet. Exact’s test could compete with ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

US diagnostic company Exact Sciences has announced its blood-based colorectal cancer (CRC) screening test algorithm showed a sensitivity of 88% for colorectal cancer and 31% for advanced ...

Analysts also raised price targets for Applovin and Arm Holdings. Wall Street Analysts Believe Exact Sciences Could Rally 34.33%: Here's is How to Trade Exact Sciences (NASDAQ: EXAS) closed the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...